The rebel angel: Mutant p53 as the driving oncogene in breast cancer

Carcinogenesis

Volumn 33, Issue 11, 2012, Pages 2007-2017

  Walerych, Dawid ^a   Napoli, Marco ^a,b   Collavin, Licio ^a,b   Del Sal, Giannino ^a,b  

^a Laboratorio Nazionale CIB LNCIB   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CARCINOGENICITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; MISSENSE MUTATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TP53 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; WILD TYPE;

BREAST NEOPLASMS; FEMALE; GENES, P53; HUMANS; MUTATION; ONCOGENES;

EID: 84868613148     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs232     Document Type: Review

References (171)

1. Horn, H.F. et al. (2007) Coping with stress: multiple ways to activate p53. Oncogene, 26, 1306-1316.
2. Li, T. et al. (2012) Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence. Cell, 149, 1269-1283.
3. Forbes, S.A. et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res., 39, D945-50.
4. Petitjean, A. et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat., 28, 622-629.
5. Feki, A. et al. (2004) Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol., 52, 103-116.
6. Olivier, M. et al. (2001) TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin. Cancer Biol., 11, 353-360.
7. Hill, K.A. et al. (2002) p53 as a mutagen test in breast cancer. Environ. Mol. Mutagen., 39, 216-227.
8. Greenblatt, M.S. et al. (2001) TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res., 61, 4092-4097.
9. Manié, E. et al. (2009) High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res., 69, 663-671.
10. Langerød, A. et al. (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol. Biomarkers Prev., 11, 1684-1688.
11. Nedelcheva Kristensen, V. et al. (1998) Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics, 8, 441-447.
12. Malkin, D. (2011) Li-fraumeni syndrome. Genes Cancer, 2, 475-484.
13. Olivier, M. et al. (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol., 2, a001008.
14. Garritano, S. et al. (2010) Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum. Mutat., 31, 143-150.
15. Assumpção, J.G. et al. (2008) Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer, 8, 357.
16. Bull, S.B. et al. (2004) The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J. Clin. Oncol., 22, 86-96.
17. Olivier, M. et al. (2006) The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin. Cancer Res., 12, 1157-1167.
18. Wiechmann, L. et al. (2008) The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer, 112, 2130-2142.
19. Bombonati, A. et al. (2011) The molecular pathology of breast cancer progression. J. Pathol., 223, 307-317.
20. Navin, N. et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature, 472, 90-94.
21. Gerlinger, M. et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med., 366, 883-892.
22. Wolf, D. et al. (1984) Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell, 38, 119-126.
23. Halevy, O. et al. (1990) Different tumor-derived p53 mutants exhibit distinct biological activities. Science, 250, 113-116.
24. Dittmer, D. et al. (1993) Gain of function mutations in p53. Nat. Genet., 4, 42-46.
25. Liu, G. et al. (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl. Acad. Sci. U.S.A., 97, 4174-4179.
26. Olive, K.P. et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell, 119, 847-860.
27. Lang, G.A. et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell, 119, 861-872.
28. Donehower, L.A. et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
29. Jacks, T. et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4, 1-7.
30. Wijnhoven, S.W. et al. (2005) Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res., 65, 8166-8173.
31. Speidel, D. et al. (2006) Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. Oncogene, 25, 940-53.
32. Clore, G.M. et al. (1994) High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science, 265, 386-391.
33. Cho, Y. et al. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265, 346-355.
34. Bullock, A.N. et al. (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene, 19, 1245-1256.
35. Kato, S. et al. (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U.S.A., 100, 8424-8429.
36. Deissler, H. et al. (2004) Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol. Rep., 11, 1281-1286.
37. Bertheau, P. et al. (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med., 4, e90.
38. Jordan, J.J. et al. (2010) Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol. Cancer Res., 8, 701-716.
39. Neilsen, P.M. et al. (2011) Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget., 2, 1203-1217.
40. Chicas, A. et al. (2000) Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem. Biophys. Res. Commun., 279, 383-390.
41. Scian, M.J. et al. (2004) Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene, 23, 4430-4443.
42. Weisz, L. et al. (2004) Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res., 64, 8318-8327.
43. Yan, W. et al. (2009) Identification of GRO1 as a critical determinant for mutant p53 gain of function. J. Biol. Chem., 284, 12178-12187.
44. Fontemaggi, G. et al. (2009) The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat. Struct. Mol. Biol., 16, 1086-1093.
45. Donzelli, S. et al. (2011) MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ., 19, 1038-1048.
46. Suzuki, H.I. et al. (2009) Modulation of microRNA processing by p53. Nature., 460, 529-533.
47. Dell'Orso, S. et al. (2011) ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. OMICS., 15, 305-312.
48. Girardini, J.E. et al. (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell., 20, 79-91.
49. Martynova, E. et al. (2012) Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget, 3, 132-143.
50. Chène, P. (1998) In vitro analysis of the dominant negative effect of p53 mutants. J. Mol. Biol., 281, 205-209.
51. Wijnhoven, S.W. et al. (2007) Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res., 67, 4648-4656.
52. Chan, W.M. et al. (2004) How many mutant p53 molecules are needed to inactivate a tetramer? Mol. Cell. Biol., 24, 3536-3551.
53. Monti, P. et al. (2011) Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. Mol. Cancer Res., 9, 271-279.
54. Stoczynska-Fidelus, E. et al. (2011) Limited importance of the dominant-negative effect of TP53 missense mutations. BMC Cancer, 11, 243.
55. Junk, D.J. et al. (2008) Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia, 10, 450-461.
56. Bond, G.L. et al. (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets, 5, 3-8.
57. Terzian, T. et al. (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev., 22, 1337-1344.
58. Lukashchuk, N. et al. (2007) Ubiquitination and degradation of mutant p53. Mol. Cell. Biol., 27, 8284-8295.
59. Zhang, J. et al. (2006) p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res., 66, 10325-10331.
60. Muller, P. et al. (2008) Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene, 27, 3371-3383.
61. Matsumoto, M. et al. (2006) Posttranslational phosphorylation of mutant p53 protein in tumor development. Med. Mol. Morphol., 39, 79-87.
62. Dai, C. et al. (2010) p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med., 16, 528-536.
63. Minamoto, T. et al. (2001) Distinct pattern of p53 phosphorylation in human tumors. Oncogene, 20, 3341-3347.
64. Yap, D.B. et al. (2004) Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res., 64, 4749-4754.
65. Perez, R.E. et al. (2010) Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J. Cell. Physiol., 225, 394-405.
66. Dötsch, V. et al. (2010) p63 and p73, the ancestors of p53. Cold Spring Harb. Perspect. Biol., 2, a004887.
67. Collavin, L. et al. (2010) p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ., 17, 901-911.
68. Melino, G. (2011) p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ., 18, 1487-1499.
69. Zawacka-Pankau, J. et al. (2010) p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle, 9, 720-728.
70. Gaiddon, C. et al. (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol., 21, 1874-1887.
71. Strano, S. et al. (2000) Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem., 275, 29503-29512.
72. Strano, S. et al. (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem., 277, 18817-18826.
73. Xu, J. et al. (2011) Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol., 7, 285-295.
74. Di Como, C.J. et al. (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol., 19, 1438-1449.
75. Adorno, M. et al. (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell, 137, 87-98.
76. Muller, P.A. et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell, 139, 1327-1341.
77. Khoury, M.P. et al. (2011) p53 Isoforms: An Intracellular Microprocessor? Genes Cancer, 2, 453-465.
78. Bourdon, J.C. et al. (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev., 19, 2122-2137.
79. Bourdon, J.C. et al. (2011) p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res., 13, R7.
80. Ellis, P.A. et al. (1997) Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br. J. Cancer, 76, 480-485.
81. Zhan, Q. et al. (1996) Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation. DNA Cell Biol., 15, 805-815.
82. Bruno, T. et al. (2010) Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. Cancer Cell, 18, 122-134.
83. Suh, Y.A. et al. (2011) Multiple stress signals activate mutant p53 in vivo. Cancer Res., 71, 7168-7175.
84. Song, H. et al. (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol., 9, 573-580.
85. Hanel, W. et al. (2012) Links between mutant p53 and genomic instability. J. Cell. Biochem., 113, 433-439.
86. Jain, A.N. et al. (2001) Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc. Natl. Acad. Sci. U.S.A., 98, 7952-7957.
87. Jong, Y.J. et al. (2004) Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. Cancer Genet. Cytogenet., 148, 55-65.
88. Murphy, K.L. et al. (2000) A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J., 14, 2291-2302.
89. Bossi, G. et al. (2006) Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene, 25, 304-309.
90. Lim, L.Y. et al. (2009) Mutant p53 mediates survival of breast cancer cells. Br. J. Cancer, 101, 1606-1612.
91. Stambolsky, P. et al. (2010) Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell, 17, 273-285.
92. Végran, F. et al. (2007) Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene, 26, 290-297.
93. Pratt, M.A. et al. (2007) Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells. Apoptosis, 12, 657-669.
94. Tawfik, K. et al. (2012) Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Hum. Pathol., 43, 23-30.
95. Gollahon, L.S. et al. (1996) Immortalization of human mammary epithelial cells transfected with mutant p53 (273his). Oncogene, 12, 715-725.
96. Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. U.S.A., 107, 246-251.
97. Skinner, H.D. et al. (2012) TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin. Cancer Res., 18, 290-300.
98. Liu, G. et al. (2000) Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res., 60, 1810-1814.
99. Fernández-Cuesta, L. et al. (2011) Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Res. Treat., 125, 35-42.
100. Menendez, D. et al. (2010) Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc. Natl. Acad. Sci. U.S.A., 107, 1500-1505.
101. Konduri, S.D. et al. (2010) Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc. Natl. Acad. Sci. U.S.A., 107, 15081-15086.
102. Liu, W. et al. (2006) Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J. Biol. Chem., 281, 9837-9840.
103. Sayeed, A. et al. (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res., 67, 7746-7755.
104. Freed-Pastor, W.A. et al. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell, 148, 244-258.
105. Aziz, S.A. et al. (2001) Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J., 7, 398-404.
106. Dawood, S. et al. (2011) Inflammatory breast cancer: what progress have we made? Oncology (Williston Park, N.Y.), 25, 264-70, 273.
107. Weisz, L. et al. (2007) Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res., 67, 2396-2401.
108. Yeudall, W.A. et al. (2012) Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis, 33, 442-451.
109. Kelavkar, U.P. et al. (1999) Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene. Proc. Natl. Acad. Sci. U.S.A., 96, 4378-4383.
110. Reddy, N. et al. (1997) Characterization of a 15-lipoxygenase in human breast carcinoma BT-20 cells: stimulation of 13-HODE formation by TGF alpha/EGF. Biochem. Biophys. Res. Commun., 231, 111-116.
111. Werner, H. et al. (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. U.S.A., 93, 8318-8323.
112. Gallagher, E.J. et al. (2011) Minireview: IGF, Insulin, and Cancer. Endocrinology, 152, 2546-2551.
113. Morselli, E. et al. (2008) Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle, 7, 3056-3061.
114. Debnath, J. (2011) The multifaceted roles of autophagy in tumors-implications for breast cancer. J. Mammary Gland Biol. Neoplasia, 16, 173-187.
115. Kieser, A. et al. (1994) Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9, 963-969.
116. Linderholm, B.K. et al. (2001) The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res., 61, 2256-2260.
117. Kalluri, R. et al. (2009) The basics of epithelial-mesenchymal transition. J. Clin. Invest., 119, 1420-1428.
118. Roger, L. et al. (2010) Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J. Cell. Sci., 123(Pt 8), 1295-1305.
119. Kogan-Sakin, I. et al. (2011) Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ., 18, 271-281.
120. Ohashi, S. et al. (2010) Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res., 70, 4174-4184.
121. Zhang, Y. et al. (2011) Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J. Biol. Chem., 286, 16218-16228.
122. Mani, S.A. et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-715.
123. Cicalese, A. et al. (2009) The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell, 138, 1083-1095.
124. Mizuno, H. et al. (2010) Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc. Natl. Acad. Sci. U.S.A., 107, 22745-22750.
125. Pece, S. et al. (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell, 140, 62-73.
126. Sarig, R. et al. (2010) Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J. Exp. Med., 207, 2127-2140.
127. Brosh, R. et al. (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer, 9, 701-713.
128. Perou, C.M. et al. (2000) Molecular portraits of human breast tumours. Nature, 406, 747-52.
129. Sorlie, T. et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A., 98, 10869-74.
130. Curtis, C. et al. (2012) The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature. 486, 346-352.
131. Rahko, E. et al. (2003) A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur. J. Cancer, 39, 447-453.
132. Yamashita, H. et al. (2004) Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res., 6, R24-R30.
133. Shah, S.P. et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature., 486, 395-399.
134. King, S.I. et al. (2012) Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. Breast Cancer Res., 14, E-pub.
135. Lowe, S.W. et al. (1994) p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
136. O'Connor, P.M. et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57, 4285-4300.
137. Wahl, A.F. et al. (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2, 72-79.
138. Bonnefoi, H. et al. (2011) TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol., 12, 527-539.
139. Ma, C.X. et al. (2012) Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J. Clin. Invest., 122, 1541-1552.
140. Jackson, J.G. et al. (2012) p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer. Cancer Cell, 21, 793-806.
141. Selivanova, G. et al. (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med., 3, 632-638.
142. Friedler, A. et al. (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. U.S.A., 99, 937-942.
143. Martynova, E. et al. (2012) Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget, 3, 132-143.
144. Boeckler, F.M. et al. (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. U.S.A., 105, 10360-10365.
145. Guida, E. et al. (2008) Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res., 68, 6550-6558.
146. Foster, B.A. et al. (1999) Pharmacological rescue of mutant p53 conformation and function. Science, 286, 2507-2510.
147. Weinmann, L. et al. (2008) A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/ TRAIL-induced apoptosis. Cell Death Differ., 15, 718-729.
148. Kravchenko, J.E. et al. (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc. Natl. Acad. Sci. U.S.A., 105, 6302-6307.
149. Bykov, V.J. et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med., 8, 282-288.
150. Bykov, V.J. et al. (2005) PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene, 24, 3484-3491.
151. Wiman, K.G. (2010) Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene, 29, 4245-4252.
152. Valenti, F. et al. (2011) Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle, 10, 4330-4340.
153. Li, D. et al. (2011) Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res., 9, 577-588.
154. Li, D. et al. (2011) SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ., 18, 1904-1913.
155. Yan, W. et al. (2012) Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene. doi: 10.1038/onc.2012.81
156. Walerych, D. et al. (2009) Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions. Oncogene, 28, 4284-4294.
157. Mantovani, F. et al. (2007) The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat. Struct. Mol. Biol., 14, 912-920.
158. Blagosklonny, M.V. et al. (1995) Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11, 933-939.
159. Zhang, F. et al. (2011) MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem. Pharmacol., 82, 24-34.
160. Going, J.J. et al. (2007) Aberrant expression of TopBP1 in breast cancer. Histopathology, 50, 418-424.
161. Liu, K. et al. (2009) Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol. Cell. Biol., 29, 2673-2693.
162. Liu, K. et al. (2011) TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol. Cell. Biol., 31, 4464-4481.
163. Jeffrey, P.D. et al. (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science, 267, 1498-1502.
164. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
165. Solomon, H. et al. (2011) Mutant p53 gain of function is interwoven into the hallmarks of cancer. J. Pathol., 225, 475-478.
166. Krepulat, F. et al. (2005) Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice. Oncogene, 24, 4645-4659.
167. Heinlein, C. et al. (2008) Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int. J. Cancer, 122, 1701-1709.
168. Di Agostino, S. et al.. (2008) The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle, 7, 3440-3447.
169. Di Agostino, S. et al. (2006) Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell, 10, 191-202.
170. Li, B. et al. (1998) A transgenic mouse model for mammary carcinogenesis. Oncogene, 16, 997-1007.
171. Modi, S. et al. (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer. Res., 17, 5132-9.